Necrosis has been a profound hurdle in the treatment of chronic disease, as well as in fields such as tissue engineering, organ preservation and beyond. Our Anti-Necrotics™ hold the potential to revolutionize these fields. Our data (independently validated by three reputed CROs) has been shown to block necrosis by an unprecedented 90%.
Additionally, we are advancing several exploratory programs in senescent cells, oncology, microbiome-drug interaction, and inflammatory bowel disease. These programs leverage our Blueprint Maps to identify novel targets.
Anti-Necrotics™: Clinical Pipeline
studies
Approximately 20% of hospital admissions result in acute kidney injury, making it a common and severe complication in hospitalized patients. It is also the key risk faced by astronauts in space. To date, there is no treatment other than dialysis or organ replacement. Our Anti-Necrotics™ hold promise to be a first-in-class treatment, blocking the common endpoint of all factors giving rise to this deadly condition.
Anti-Necrotics™: Non-Clinical Pipeline
Necrosis in cell culture imposes significant costs on optimizing media to sustain primary cells for R&D. Our Anti-Necrotics™ will enable the harvesting and extended viability of a broader range of primary cells, thereby driving innovation forward and significantly reducing costs. The cell culture media market is rapidly growing and projected to reach $13.0 billion by 2028.
Necrotic cores have long been the major obstacle in tissue engineering. Our Anti-Necrotics™ promise to overcome this challenge, enabling the growth of complex lab-grown tissues and organs for the first time. This innovation could revolutionize treatments for bowel conditions, provide replacement organs, and support space missions, ushering in a new era of bioengineered tissues and organs.
Our Anti-Necrotics could transform organ transplantation by significantly extending preservation windows. This breakthrough addresses the critical issue of organ shortages: 17 daily deaths in the U.S. alone and a new addition to the transplant waiting list every 9 minutes, offering new hope to countless patients.
